TLDR
- Phio stock jumps 43% after trial confirms strong safety and tumor response
- Cancer trial success sends PHIO shares higher on clean safety results
- PHIO rallies as early cancer data shows no serious safety concerns
- Phio climbs 43% after positive safety review of PH-762 cancer study
- Strong trial response pushes PHIO stock sharply higher in volatile trade
Phio Pharmaceuticals (PHIO) stock jumps 43% as cancer trial shows strong safety and response rates, lifting shares to $1.285. The rally followed clinical updates and triggered heavy intraday swings, yet buyers defended levels above $1.20. Consequently, Phio Pharmaceuticals Corp. stock jumped 43% as traders reacted to encouraging trial safety signals.
Phio Pharmaceuticals Corp., PHIO
Trial safety review confirms clean early profile
The company advanced its oncology program after regulators completed a planned safety review of the Phase 1b study. Investigators reported no dose-limiting toxicities across all treated patients during the monitored period. Phio Pharmaceuticals Corp. stock jumped 43% as the clean safety profile strengthened market confidence.
The study evaluated the INTASYL compound PH-762 through escalating concentrations across five separate dosing cohorts. Researchers increased drug concentration twentyfold from the first cohort to the final cohort. As a result, safety outcomes remained stable even at the highest exposure level.
All enrolled participants completed four intratumoral injections and finished at least four weeks of follow-up monitoring. Furthermore, the review covered twenty-two patients with various cutaneous carcinoma diagnoses. Consistent tolerability supported continued evaluation of the program at advanced dosing levels.
Response rates highlight early clinical activity
Pathological analysis showed measurable tumor clearance in a majority of treated squamous cell carcinoma cases. The dataset indicated a reported response rate of sixty-five percent among evaluated patients. Therefore, Phio Pharmaceuticals Corp. Stock jumps 43% as response metrics added clinical weight.
Thirteen of twenty squamous cell carcinoma patients achieved meaningful pathological responses after treatment completion. Nine patients reached complete tumor clearance with no residual detectable disease. Two others recorded near-complete responses, and two posted partial but clinically relevant reductions.
No participant experienced documented disease progression during the monitored treatment window. Moreover, one metastatic Merkel cell carcinoma patient achieved a partial response under the same dosing framework. Consequently, the early activity profile suggested biological engagement without observed acceleration of disease.
Regulatory planning and manufacturing timeline advance
The company plans to submit regulatory materials seeking guidance on the next trial design during the second quarter of 2026. Phio Pharmaceuticals Corp. Stock jumps 43% as timelines aligned with continued development milestones. The submission aims to shape a pathway toward a pivotal human study.
Chemistry and manufacturing teams also advanced drug substance preparation for future non-human primate testing requirements. Management expects material availability during March 2026 to support prerequisite safety studies. These steps maintain alignment with the broader clinical schedule.
Process development and impurity testing continue under established manufacturing standards and internal documentation targets. Furthermore, the company projects cGMP production during the second half of 2026. Phio Pharmaceuticals Corp. Stock jumped 43% as operational progress matched clinical momentum.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
